



Facts About Overactive Bladder (OAB)

About OAB OAB is characterized by a sudden, uncomfortable need to urinate with or without urge incontinence (urine leakage). It usually includes more frequent urination and nocturia (waking up at least once during the night to urinate). More than an “inconvenience,” the condition can be disabling and is associated with a marked decrease in health-related quality of life as well as higher rates of depression.

Affected Population OAB affects as many as 33 million adults in the U.S. – more than diabetes or asthma. The disease affects both men and women, however women experience more severe symptoms earlier in life (a marked increase after 44 years of age as compared to 64 years of age among men), resulting in a diminished capacity to function physically, socially and emotionally at a time when many women are still active, working and busy with their families.

Symptoms OAB occurs when smooth muscle of the bladder contracts while the bladder is filling with urine, rather than staying at rest. The symptoms of OAB include increased urinary urgency or leakage, and frequent urination at night.

Impact of OAB Compared to people without OAB, those with OAB report:

- Disturbed sleep, overeating, poor self-esteem
- Higher rates of hypertension, obesity and even arthritis
- 20 percent more visits to the physician
- 138 percent more urinary tract infections

Treatment Options The treatment of OAB includes behavioral changes such as bladder training exercises (Kegel exercises), managing fluid intake, and anticholinergic medication, which relax the muscles around the bladder. In some rare cases, surgery might be performed to enlarge the bladder.

The oral anticholinergic agents currently available are commonly associated with drying side effects (e.g., dry mouth, constipation) and high rates of discontinuation.

Recently, the U.S. Food and Drug Administration (FDA) approved GELNIQUE™ (oxybutynin chloride) Gel 10%, a clear and colorless, fragrance-free,

hydroalcoholic gel that provides for delivery of oxybutynin hydrochloride in an innovative transdermal form. GELNIQUE will provide OAB patients an effective and novel alternative to currently available oral treatment options.

GELNIQUE is approved for the treatment of OAB with symptoms of urge urinary incontinence, urgency and frequency.

In a clinical trial, treatment was well tolerated with a low incidence of adverse events and no treatment-related serious adverse events. The most frequently reported treatment-related adverse events (>2% and greater than placebo) were dry mouth (6.9%) and application-site reactions (5.4%).